★ INSERT COIN◆NOW PLAYING: VENTURES◆HIGH SCORE: $100M ARR◆★ NEW STAGE UNLOCKED: ABOUT ME◆PRESS START◆★ DEMO DAY 04:00:00◆
★ INSERT COIN◆NOW PLAYING: VENTURES◆HIGH SCORE: $100M ARR◆★ NEW STAGE UNLOCKED: ABOUT ME◆PRESS START◆★ DEMO DAY 04:00:00◆
◀ BACK TO FEED
NEWS★ LIFE SCIENCES / BIOTECHNOV 11, 2026

Switchpoint Bio raises $5.3m to track treatment response through blood

Switchpoint Bio is developing blood-based epigenomic measurements to help drug developers follow biological changes during treatment.

Switchpoint Bio raises $5.3m to track treatment response through blood

Knowing whether a treatment helped is one question. Understanding what changed inside the body is another.

What happened

Switchpoint Bio disclosed $5.3 million in pre-seed financing, including $5 million from Treehouse Delmar Investments.

The company is developing a platform that combines blood-based DNA-methylation measurements with AI analysis. The funding supports clinical and industry validation, expanded datasets and growth of its scientific and technical team.

Why it matters

Repeated measurements can help researchers study how a patient's biology changes during treatment. Blood sampling offers a practical way to collect information over time, alongside other clinical evidence.

The bigger picture

More precise drug development needs tools for observing response as well as tools for discovering molecules. Switchpoint is building a measurement layer intended to help researchers investigate which biological mechanisms change, persist or resist treatment.

#SWITCHPOINT BIO#EPIGENOMICS#DRUG DEVELOPMENT#BIOTECH